Selecta Biosciences (SELB) – P3 readout in 2H 2021, but commercial rights are granted to someone else, therefore somewhat limited upside. As of 6/3/21 had market cap of $508M with SP around $4.40.
Novan, Inc. (NOVN) – P3 readout is any day in 2Q. If they don’t hit their endpoint the company will be finished. Good upside if P3 is successful. To close to readout to make a FN page. As of 6/5/21 had market cap of $118M with SP around $7.80.
BioMx, Inc. (PHGE) – P3 readout on Acne coming up, but company is a wide variety of drugs for different indications. Not ideal from a FN perspective – like companies that are focused and have a deep knowledge of specialized indications. As of 7/4/21 had a MC of $124M with a SP of $5.10.
Aravive, Inc. (ARAV) – Just started P3 trial – data not due until July 2023, at the earliest. Company will be doing considerable dilution to fund the trial. As of 10/22/21 had a MC of $74M with a SP of $3.60.
NuCana, Inc. (NCNA) – Just started P3 trial – data not due until 2024, at the earliest. Protide technology look extremely promising. Company will be doing some dilution to fund the trial. As of 10/29/21 had a MC of $124M with a SP of $2.40.